| Name | Title | Contact Details |
|---|
gm3 is the leading web3-native professional services firm. We are dedicated to being the trusted partner of choice for companies and investors looking to navigate the exciting world of web3. Our mission is to provide expert consulting services that empower our clients to unlock the full potential of this transformative technology. gm3 Ventures connects Founders & Investors. For aspiring entrepreneurs, we offer a comprehensive range of financing services tailored to your specific needs. For investors, we provide access to diversified investment opportunities in the web3 ecosystem. With our rigorous due diligence process and curated network, we ensure quality deal flow. gm3 Research specializes in high-end, commissioned research and whitepaper curation across the web3, decentralized finance and technology spaces. Our commitment to excellence is led by Crypto Punk and Harvard University PhD, Dr. Michael Frisch. Together with our team of field experts, we illuminate the path to informed decision-making in the dynamic landscape of web3. gm3 Advisory provides tailored advice and strategic guidance to unlock the potential of web3 for both traditional companies exploring the space and web3-native companies looking to structure and scale their businesses. gm3 Curation offers luxury concierge services across physical art, digital art and high-end fashion. Our creative agency partnership has curated collections for some of the biggest high-end fashion brands in the world. The name gm3 stems from the ubiquitous gm (good morning) greeting that prevails in the decentralized finance & technology spaces. The number 3 represents the last digit in the term web3, which represents the 3rd major evolution of the internet.
The PAISBOA Health Benefit Trust (HBT) is a consortium of independent schools, colleges, and universities within the state of Pennsylvania. The sole focus of the HBT is to provide high-quality health plans at affordable rates. Members enjoy savings, stability, and innovative programs through scale and collaboration. The PAISBOA HBT is a self-funded entity, organized as a Multiple Employer Welfare Association (MEWA). While the HBT was established by and exists for the benefit of its member institutions, it is governed by a dedicated Board of Trustees who are elected by the members to ensure that the needs of all of the enrolled participants are represented.
Welcome to The IN Group! The IN Group (TIG) beautifully brings together the magic of the group individual brands, Investigo, InX, Definia, Caraffi, Sigma Labs & BioTalent enabling us to design truly bespoke solutions. Our mission is simple - to unlock the power of people. We know that conventional recruitment cant always solve todays talent challenges, so we decided to break with convention and offer you SO much more with TIG. Meet our brands - Investigo – we recruit the talent you need - InX – we find the best leaders - Definia – we deliver digital programmes - Caraffi – we offer talent advisory & talent solutions (EVP/CVP/MSP/RPO) - Sigma Labs - we offer outstanding graduates amplified with exceptional training in the world of Tech - BioTalent - we offer life sciences recruitment with the means to nurture change-makers Unashamedly human talent solutions At the IN Group, were unashamedly human, were encourage to be our true self and we love what we do. We think youll feel this through the people you meet, the solutions we design and the results youll enjoy. We believe that when people rally behind an ambitious vision and a brilliant culture, it lights up every corner of your organisation. We believe in people, so they make change for better. Wed love to tell you more so come and say hello@wearetig.com and well tell you all about it!
Dashen Bank is one of the leading banks in Ethiopia with over 860 branches and banking outlets.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.